Online inquiry

IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13372MR)

This product GTTS-WQ13372MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LRRC15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001135057.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 131578
UniProt ID Q8TF66
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13372MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1291MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ9168MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ14665MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ1200MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ6986MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ETI-204
GTTS-WQ4094MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-204
GTTS-WQ8649MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ4920MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW